Shen, L., Shitara, K., Mei, Q., Li, C., Wei, J., Xie, X., Chen, P., Li, Z., Zhang, N., Zhang, Y., Sheng, L., Chen, X., Guo, Q., Yang, J., Liu, Z., Liang, X., Liu, M., Jin, Y., Gong, Z., Zhou, H. (2025). A multiregional, randomized, controlled, open-label, phase 3 study of the anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) arcotatug tavatecan (IBI343) in gastric or gastroesophageal junction adenocarcinoma (G/GEJA): Trial in progress.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps4201